about
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsCirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infectionClinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution.Complex Genotype Mixtures Analyzed by Deep Sequencing in Two Different Regions of Hepatitis B Virus.Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection.Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencingQuasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genomeDeep sequencing in the management of hepatitis virus infections.Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype.High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping.Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing.Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing.Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.IL28B genetic variation and hepatitis C virus-specific CD4(+) T-cell responses in anti-HCV-positive blood donors.Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D.Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy.Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model.Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment.Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy.Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population.HBV core region variability: effect of antiviral treatments on main epitopic regions.Amino acid substitutions within HLA-B*27-restricted T cell epitopes prevent recognition by hepatitis delta virus-specific CD8+ T cells.Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy.Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up studyHDV evolution-will viral resistance be an issue in HDV infection?Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategyCharacterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection
P50
Q28484005-4CDD2857-889D-49EC-B9D7-CE5093C202FCQ28652352-98553FEC-294A-4299-BF31-FDA60164E78DQ33961593-8D26DBBF-ED5D-4FF2-94D5-5BF6279197D0Q34506624-F386CD96-A8D3-47B1-937F-FEF354DF2379Q35880685-560DC7FA-B80C-439F-88CE-2BA0AE682877Q36065068-D9FB7BD4-4308-4410-B517-0A32B9971DD9Q36395364-18C82A67-BDD3-4E4A-BA7A-C57BC85457F4Q37285249-69147061-1650-4275-ADBA-BFB9D40D63CEQ38830111-C8241316-CC2A-4738-AD16-A1128931044AQ39063756-4980AD1E-E322-4819-94DF-C568FBE605B5Q40251459-9B4D23F4-02CF-46E1-ADF0-8A1E9DD07CB2Q40294468-D4239BE7-1FD5-426B-826D-2EDD5B9E3566Q40335058-CB98236A-54E8-471B-A2A4-CA25851356F7Q40384629-704839C2-F790-4ED9-921A-C487C6FEFA0BQ40419604-4134581B-DB84-4F12-BB57-CE1A1EB8B2BDQ41163712-E066CA6D-E417-4799-A020-998151504362Q41922052-A83952CD-5D2C-4C4A-83B4-0E2AFF41E28CQ42173073-934C2E73-5A25-4E48-9F89-30E9DA06D3BBQ42985791-38B2DC49-C8B9-4923-B147-C6A200810FBEQ43117100-C92C17C8-6BCC-46B8-B370-C4DF4EF98E04Q43179791-2EACAD18-D1A9-4003-981D-084779FD206CQ44131409-C786007A-0129-4B10-9ED0-616D86E09E9CQ45352035-A0AC1F00-95A0-44FA-9243-CD71F5EBE4E4Q45376971-BACB25D3-9342-4124-870E-BFA197B157FCQ46587742-8B23E9FA-1A6E-4F12-BECA-9B434A357276Q49885474-1A0140B5-0713-41C2-8D75-C7533DD14F9EQ50545949-CF3BE7B3-85EF-447B-928A-3CE5ED41611FQ53822443-7B8BB93B-0183-4D26-BB47-BBE3A70D6488Q55259180-890DE5C9-9360-4734-A68A-1197017BE65BQ57097288-549313FB-3DE9-4FA9-9A65-A804A4AE82A8Q58578646-05E9CC3E-563C-4E68-8AE0-B533C0EEECA6Q58861550-B40EF25E-DB9A-4E37-AC31-3565ED97E437Q64069284-4FFB7CC2-2C6A-42D8-B16A-7C9C7FA67A43
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Tabernero
@ast
David Tabernero
@en
David Tabernero
@es
David Tabernero
@nl
type
label
David Tabernero
@ast
David Tabernero
@en
David Tabernero
@es
David Tabernero
@nl
prefLabel
David Tabernero
@ast
David Tabernero
@en
David Tabernero
@es
David Tabernero
@nl
P106
P1153
22037019200
P21
P31
P496
0000-0002-1146-4084